CELEX: 32019M9583
Language: en
Date: 2019-12-10 00:00:00
Title: Commission Decision of 10/12/2019 declaring a concentration to be compatible with the common market (Case No COMP/M.9583 - TPG / HONG LEONG GROUP / COLUMBIA ASIA HEALTHCARE) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

EUROPEAN COMMISSION
                                                                Brussels,10.12.2019
                                                                C(2019) 9075 final
                                                                                 PUBLIC VERSION
                                                                To the notifying parties
Subject:        Case M.9583 – TPG / HONG LEONG GROUP / COLUMBIA ASIA
                HEALTHCARE
                Commission decision pursuant to Article 6(1)(b) of Council Regulation
                                       1
                (EC) No 139/2004 and Article 57 of the Agreement on the European
                                    2
                Economic Area
Dear Sir or Madam,
1.      On 18 November 2019, the European Commission received notification of a proposed
        concentration pursuant to Article 4 of the Merger Regulation by which the
        undertakings TPG Asia VI SF Pte. Ltd. (‘TPG Asia’, Singapore), belonging to TPG,
        USA, and Hong Leong Healthcare Group Sdn Bhd (‘Hong Leong’, Malaysia),
        belonging to Hong Leong Group, Malaysia, acquire within the meaning of Article
        3(1)(b) and 3(4) of the Merger Regulation joint control over the whole of the
        undertaking Columbia Asia Healthcare Pte. Ltd. (‘CAHSG’, Singapore) by way of
        purchase of shares.3
2.      The business activities of the undertakings concerned are:
             for TPG Asia: part of TPG, a private investment firm that manages a family of
              funds that invest in a variety of companies through acquisitions and corporate
              restructurings. TPG Asia forms part of the TPG Capital Asia platform, which
              focuses on Asian investments,
             for Hong Leong: part of Hong Leong Group, a conglomerate with diversified
              businesses in banking and financial services, manufacturing and distribution,
              property development and investments, hospitality, and leisure. Hong Leong was
              established on August 20, 2019 for the purpose of acquiring CAHSG and will
              focus on the healthcare sector,
1       OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’). With effect from 1 December 2009, the Treaty on
        the Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the
        replacement of ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology
        of the TFEU will be used throughout this decision.
2       OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).
3       Publication in the Official Journal of the European Union No C 400, 26.11.2019, p. 20.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.
 ---pagebreak---        for CAHSG: the holding entity for the Columbia Asia Group, a private healthcare
        company founded in 1996 to provide accessible, affordable, and high-quality
        healthcare to meet the needs of the Asian population. CAHSG has 18 facilities
        across Asia: 12 hospitals in Malaysia, 2 hospitals and 1 clinic in Vietnam, and 3
        hospitals in Indonesia. It currently also operates 11 hospitals in India, which will
        be carved out from the transaction perimeter.
3. After examination of the notification, the European Commission has concluded that
   the notified operation falls within the scope of the Merger Regulation and of
   paragraph 5(a) of the Commission Notice on a simplified procedure for treatment of
   certain concentrations under Council Regulation (EC) No 139/2004.4
4. For the reasons set out in the Notice on a simplified procedure, the European
   Commission has decided not to oppose the notified operation and to declare it
   compatible with the internal market and with the EEA Agreement. This decision is
   adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of
   the EEA Agreement.
                                                    For the Commission
                                                    (Signed)
                                                    Cecilio MADERO VILLAREJO
                                                    Acting Director-General
4  OJ C 366, 14.12.2013, p. 5.
                                                2